187 related articles for article (PubMed ID: 32017375)
21. Simplified flow cytometric assessment in mycosis fungoides and Sézary syndrome.
Hristov AC; Vonderheid EC; Borowitz MJ
Am J Clin Pathol; 2011 Dec; 136(6):944-53. PubMed ID: 22095381
[TBL] [Abstract][Full Text] [Related]
22. The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome.
Rittig AH; Lindahl LM; Johansen C; Celis P; Ødum N; Iversen L; Litman T
Acta Derm Venereol; 2019 Nov; 99(12):1148-1153. PubMed ID: 31453630
[TBL] [Abstract][Full Text] [Related]
23. The Sézary cell in the blood of patients with mycosis fungoides.
Winkelmann RK; Hoagland HC
Dermatologica; 1980; 160(2):73-9. PubMed ID: 6965373
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
[TBL] [Abstract][Full Text] [Related]
25. PD-1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome.
Lewis NE; Gao Q; Petrova-Drus K; Pulitzer M; Sigler A; Baik J; Moskowitz AJ; Horwitz SM; Dogan A; Roshal M
Cytometry B Clin Cytom; 2022 May; 102(3):189-198. PubMed ID: 35451196
[TBL] [Abstract][Full Text] [Related]
26. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
Hughes CF; Newland K; McCormack C; Lade S; Prince HM
Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
[TBL] [Abstract][Full Text] [Related]
27. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values.
Wood GS; Hong SR; Sasaki DT; Abel EA; Hoppe RT; Warnke RA; Morhenn VB
J Am Acad Dermatol; 1990 Apr; 22(4):602-7. PubMed ID: 1690762
[TBL] [Abstract][Full Text] [Related]
28. Large cell transformation of Sézary syndrome. A conventional and molecular cytogenetic study.
So CC; Wong KF; Siu LL; Kwong YL
Am J Clin Pathol; 2000 Jun; 113(6):792-7. PubMed ID: 10874879
[TBL] [Abstract][Full Text] [Related]
29. IgG anti-50 kd lymphocyte membrane peptide antibody in patients with Sézary syndrome.
D'Ambra-Cabry K; Tharp MD; Jagasothy BV; Deng JS
J Am Acad Dermatol; 1996 May; 34(5 Pt 1):777-80. PubMed ID: 8632073
[TBL] [Abstract][Full Text] [Related]
30. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
31. Mycosis fungoides/Sézary syndrome: report of an unusual case.
Mehta A; Dhungel BM; Khan MF
J Cutan Pathol; 2006 Sep; 33 Suppl 2():12-5. PubMed ID: 16972946
[TBL] [Abstract][Full Text] [Related]
32. TRBC1 expression assessed by flow cytometry as a novel marker of clonality in cutaneous αβ T-cell lymphomas with peripheral blood involvement.
Martin-Moro F; Martin-Rubio I; Garcia-Vela JA
Br J Dermatol; 2022 Oct; 187(4):623-625. PubMed ID: 35606929
[TBL] [Abstract][Full Text] [Related]
33. Sézary cell count in exfoliative dermatitis.
Duangurai K; Piamphongsant T; Himmungnan T
Int J Dermatol; 1988 May; 27(4):248-52. PubMed ID: 2968960
[TBL] [Abstract][Full Text] [Related]
34. Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation.
Roberts AA; Amano M; Felten C; Galvan M; Sulur G; Pinter-Brown L; Dobbeling U; Burg G; Said J; Baum LG
Mod Pathol; 2003 Jun; 16(6):543-51. PubMed ID: 12808059
[TBL] [Abstract][Full Text] [Related]
35. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome.
Shono Y; Suga H; Kamijo H; Fujii H; Oka T; Miyagaki T; Shishido-Takahashi N; Sugaya M; Sato S
Acta Derm Venereol; 2019 Jul; 99(9):809-812. PubMed ID: 31045236
[TBL] [Abstract][Full Text] [Related]
36. Demonstration of a subpopulation of Ia+ T-helper cells in mycosis fungoides and the Sézary syndrome.
Hofman FM; Meyer PR; Yanagihara E; Modlin RL; Rea TH; Parker JW; Lukes RJ; Taylor CR
Am J Dermatopathol; 1983 Apr; 5(2):135-43. PubMed ID: 6224436
[TBL] [Abstract][Full Text] [Related]
37. Is there a role for epigenetic factors in the pathogenesis of epidermotropic cutaneous T-cell lymphomas (mycosis fungoides and Sézary syndrome)?
Bachelez H
Hematol J; 2001; 2(4):286-9. PubMed ID: 11920262
[No Abstract] [Full Text] [Related]
38. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
[TBL] [Abstract][Full Text] [Related]
39. A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.
Thomas BR; Whittaker S
Skin Therapy Lett; 2012 Dec; 17(10):5-9. PubMed ID: 23223768
[TBL] [Abstract][Full Text] [Related]
40. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
